Natco Pharma lines up 10 new products for domestic market
Natco Pharma will be launching about 10 new products in the domestic branded formulations segment in the present financial year and is targeting over 20 per cent growth year-on-year.The focus will... Press Release / Media Release
Natco & its alliance partner Lupin receive FDA approval for generic Lanthanum Carbonate Chewable Tablets Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for V C Nannapaneni Natco Pharma dips 12% in two days post Q1 results on profit booking
Thus far in 2017, the stock had gained 65% against 6% fall in healthcare index till Monday. Natco Pharma's Q1 net up 97%
Natco Pharma Ltd's consolidated net profit increased 97 per cent to 94 crore in the first quarter ended June 30, 2017, compared to 47.5 crore in the corresponding quarter of the previous... Press Release / Media Release
NATCO records INR 448.7 crore consolidated revenue and profit after tax of INR 93.7 crore, for the First Quarter, FY 2017-18 Board declares Interim Dividend (AGM on Sept 23, 2017)
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at their meeting held on August 07, 2017, inter alia , have approved the following :1. Recommended payment of an interim dividend of Rs.1.25 ps. (62.5%) per equity share of Rs.2/- each for the financial year 2017-18.2. The date of Annual General Meeting is on September 23, 2017 and Board had authorised Mr.V.C.Nannapaneni, Chairman and Managing Director for...